Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 28, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 254 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on July 27, 2005, and was advised to the Company on July 28, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust for current and former employees, and that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the trust shares similarly to other employees.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust to assess the significance of the 254-share transfer.
- Confirm the specific identities of the SmithKline Beecham Employee Share Option Plan 1991 participants receiving the shares.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure complete compliance regarding director interests.